# ðŸ§¬ðŸ¦  Coexistence of Potent HIV-1 Broadly Neutralizing Antibodies and Antibody-Sensitive Viruses in a Viremic Controller

## Team 4 - Irun Cohen

**Members:**
- Shea Mowry
- Han Kahvecioglu
- Maya Bartels
- Felipe Munoz
- Meghan Pinter

This team will explore the coexistence of broadly neutralizing antibodies (bNAbs) and antibody-sensitive viruses in an HIV-1 infected individual who has maintained low viral loads for over 30 years. They will focus on the mechanisms by which bNAbs contribute to viral control and the implications for designing effective HIV vaccines.

---

## Presentation Overview

**Topic:** *HIV-1 and Neutralizing Antibodies: A Battle for Control*  
**Paper Reference:**
- Natalia T. Freund, Haoqing Wang, Louise Scharf, et al.
- *Sci Transl Med* 2017; 9(373): eaal2144
- DOI: [10.1126/scitranslmed.aal2144](https://doi.org/10.1126/scitranslmed.aal2144)

### Abstract Summary ðŸ“„

The study describes an HIV-1 controller with the HLA-B57*01 and HLA-B27*05 alleles who maintained low viral loads for 30 years. The individual developed broad and potent neutralizing antibodies (bNAbs) that target multiple non-overlapping sites on the HIV-1 envelope trimer. Among these, BG18 is an antibody directed at the glycan-V3 portion of the HIV-1 envelope, representing the most potent member of its class. Single-genome sequencing revealed that 88.5% of circulating viruses remained sensitive to at least one of the coincident bNAbs. These findings suggest that combinations of bNAbs could be used to control HIV-1 infection, with potential implications for HIV vaccine development.

---

## Activities ðŸ“š

1. **30-Minute Presentation by Team Cohen (Until 4:00 PM)**  
   Team Cohen will present their analysis of the coexistence of bNAbs and antibody-sensitive viruses in HIV-1 infection. They will delve into the mechanisms of antibody-mediated control and the challenges involved in designing effective HIV vaccines.

2. **30-Minute Group Discussion (4:00 PM - 4:30 PM)**  
   The class will engage in a detailed discussion of how bNAbs contribute to viral control and what obstacles remain in the pursuit of an effective HIV vaccine. This will include a review of how the body generates bNAbs and why some viruses remain antibody-sensitive despite ongoing immune pressure.

3. **Team Tasks: Designing Effective HIV Vaccines (4:30 PM - 5:15 PM) ðŸ’¬**

---

### 3A: How do broadly neutralizing antibodies (bNAbs) affect HIV vaccine design?

**Hypothetical Study: HIV Vaccine Development Based on bNAb Responses**

- **Study Design:**  
  Researchers are developing a vaccine aimed at inducing bNAb responses in individuals at risk for HIV. The vaccine uses a combination of envelope glycoproteins from different HIV-1 strains to broaden the immune response. The primary outcome of interest is the generation of bNAbs that neutralize a wide range of HIV-1 strains.

**Key Considerations:**

- **Immunogenicity of Envelope Glycoproteins:**  
  How do different glycoproteins influence the generation of bNAbs, and what factors should be considered when choosing these antigens?

- **Autologous vs. Heterologous Strains:**  
  Should the vaccine target the individual's own viral strains (autologous) or a wide range of strains (heterologous)? How does this choice impact vaccine efficacy?

- **Combinations of bNAbs:**  
  What are the benefits and challenges of using combinations of bNAbs to control HIV, as shown in the study?

---

### 3B: What are the challenges in inducing bNAbs through vaccination?

Researchers have found that inducing bNAbs through vaccination is difficult due to the immune system's tendency to favor antibody responses to variable regions of the virus. Discuss why bNAbs are rare and the implications for vaccine design.

**Answer:**  
bNAbs target conserved regions of the HIV-1 envelope, which are often shielded by glycan structures or undergo rapid mutation. The immune system's tendency to focus on variable regions, which change frequently, makes it difficult to produce bNAbs that can neutralize a wide variety of viral strains. Vaccine strategies must therefore aim to focus immune responses on these conserved regions, potentially through sequential immunization or the use of stabilized envelope proteins.
